Literature DB >> 15887249

Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells.

Sun-Ryung Lee1, Jae-Han Park, Eui Kyun Park, Chin Ha Chung, Shin-Sung Kang, Ok-Sun Bang.   

Abstract

Akt is a key downstream effector of the PI3K signaling pathway and plays a role in cell growth and survival. Expression of a myristoylated constitutively active form of Akt (myr-Akt) in PC12 cells could override cell-growth arrest at G2/M phase and apoptosis that were induced by etoposide treatment. On the other hand, inactivation of Akt by expression of its dominant negative mutant form (km-Akt) inhibited cell proliferation by arresting the cells at G2/M phase. Expression of myr-Akt also led to an increase in the protein and mRNA levels of CDK1 and cyclin B1. Furthermore, EMSA data revealed that expression of myr-Akt promoted the binding of NF-Y to the consensus CCAAT promoter sequence, whereas expression of km-Akt almost completely abolished it. Moreover, the Akt activity was minimal in the cells that were arrested at G2/M phase by nocodazole treatment, but reached to a maximal level as the cells progressed to mitosis and G1 phase upon removal of the drug. Treatment with Akt inhibitors, but not with those of MEK or p70S6K, blocked the release of the cells from the nocodazole-induced G2/M arrest, further revealing that the Akt activity is required for G2/M phase transition. These results suggest that Akt facilitate cell-cycle progression at G2/M phase in PC12 cells and this Akt activity is correlated with upregulation of NF-Y DNA-binding activity and cyclin B1/CDK1 gene expression. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887249     DOI: 10.1002/jcp.20395

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  27 in total

1.  Nerve growth factor regulates the expression of the cholinergic locus and the high-affinity choline transporter via the Akt/PKB signaling pathway.

Authors:  Beata Madziar; Sonia Shah; Martina Brock; Rebecca Burke; Ignacio Lopez-Coviella; Ann-Christin Nickel; Esra Betul Cakal; Jan Krzysztof Blusztajn; Brygida Berse
Journal:  J Neurochem       Date:  2008-09-13       Impact factor: 5.372

2.  Insulin Signaling Regulates the FoxM1/PLK1/CENP-A Pathway to Promote Adaptive Pancreatic β Cell Proliferation.

Authors:  Jun Shirakawa; Megan Fernandez; Tomozumi Takatani; Abdelfattah El Ouaamari; Prapaporn Jungtrakoon; Erin R Okawa; Wei Zhang; Peng Yi; Alessandro Doria; Rohit N Kulkarni
Journal:  Cell Metab       Date:  2017-03-09       Impact factor: 27.287

3.  Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase.

Authors:  Weston Kenneth Ryan; Josiah Fernandez; Mikayla Katherine Peterson; David William Sheneman; Brendan Keefe Podell; Subhajyoti De; Enrique Carlo Torchia
Journal:  Cell Death Differ       Date:  2018-07-26       Impact factor: 15.828

4.  The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines.

Authors:  Katarina Matkovic; Vesna Lukinovic-Skudar; Hrvoje Banfic; Dora Visnjic
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

5.  Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.

Authors:  Xuesong Liu; Yan Shi; Keith W Woods; Paul Hessler; Paul Kroeger; Julie Wilsbacher; Jieyi Wang; Jean Y Wang; Chunying Li; Qun Li; Saul H Rosenberg; Vincent L Giranda; Yan Luo
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

6.  Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding.

Authors:  Andreas Koeberle; Hideo Shindou; Solveigh C Koeberle; Stefan A Laufer; Takao Shimizu; Oliver Werz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

7.  Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells.

Authors:  E G Russell; E C O'Sullivan; C M Miller; J Stanicka; F O McCarthy; T G Cotter
Journal:  Invest New Drugs       Date:  2014-08-10       Impact factor: 3.850

8.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

Authors:  Bryan T Hennessy; Ana-Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Z Gilcrease; Savitri Krishnamurthy; Ju-Seog Lee; Jane Fridlyand; Aysegul Sahin; Roshan Agarwal; Corwin Joy; Wenbin Liu; David Stivers; Keith Baggerly; Mark Carey; Ana Lluch; Carlos Monteagudo; Xiaping He; Victor Weigman; Cheng Fan; Juan Palazzo; Gabriel N Hortobagyi; Laura K Nolden; Nicholas J Wang; Vicente Valero; Joe W Gray; Charles M Perou; Gordon B Mills
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

9.  The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.

Authors:  Marika A Russo; Kristy S Kang; Antonio Di Cristofano
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

10.  Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.

Authors:  Huan-Tian Zhang; Dabao Zhang; Zhen-Gang Zha; Chang-Deng Hu
Journal:  Biochim Biophys Acta       Date:  2014-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.